Oakworth Capital Inc. Sells 159 Shares of Danaher Co. (NYSE:DHR)

Oakworth Capital Inc. trimmed its holdings in Danaher Co. (NYSE:DHR) by 30.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 364 shares of the conglomerate’s stock after selling 159 shares during the period. Oakworth Capital Inc.’s holdings in Danaher were worth $84,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. Heck Capital Advisors LLC acquired a new position in Danaher during the 4th quarter valued at about $27,000. Decker Retirement Planning Inc. purchased a new position in shares of Danaher during the fourth quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America bought a new stake in Danaher during the third quarter worth $39,000. MidAtlantic Capital Management Inc. purchased a new stake in Danaher in the 3rd quarter valued at $40,000. Finally, FSA Wealth Management LLC bought a new position in Danaher during the 3rd quarter valued at $50,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Performance

Shares of DHR stock opened at $209.95 on Friday. Danaher Co. has a 12 month low of $209.10 and a 12 month high of $281.70. The stock has a market capitalization of $151.64 billion, a P/E ratio of 39.76, a PEG ratio of 2.80 and a beta of 0.83. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The firm’s 50 day moving average is $233.96 and its 200 day moving average is $252.39.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period last year, the company earned $2.09 earnings per share. On average, sell-side analysts anticipate that Danaher Co. will post 7.77 earnings per share for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Friday, December 27th were issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.51%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s payout ratio is 20.45%.

Insider Activity

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This represents a 21.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 11.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

DHR has been the subject of several analyst reports. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price for the company in a report on Thursday, October 31st. KeyCorp increased their price objective on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. TD Cowen boosted their target price on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Bank of America upgraded Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target on the stock in a report on Friday, December 13th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $277.00 price objective (down previously from $299.00) on shares of Danaher in a research note on Thursday, January 30th. Seven equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.